Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells

Cellular Oncology

Volumn 37, Issue 2, 2014, Pages 119-129

  Nakaoka, Toshiki ^a   Ota, Akinobu ^b   Ono, Takayuki ^a   Karnan, Sivasundaram ^b   Konishi, Hiroyuki ^b   Furuhashi, Akifumi ^a   Ohmura, Yukinobu ^a   Yamada, Yoichi ^a   Hosokawa, Yoshitaka ^b   Kazaoka, Yoshiaki ^a  

^a AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Arsenic trioxide; Cisplatin; Oral squamous cell carcinoma; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ANNEXIN; ARSENIC TRIOXIDE; CASPASE 3; CASPASE 7; CISPLATIN; LIPOCORTIN 5; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUTH SQUAMOUS CELL CARCINOMA; MTT ASSAY; PRIORITY JOURNAL; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUTH NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOUTH NEOPLASMS; OXIDES; REACTIVE OXYGEN SPECIES;

EID: 84899654645     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0167-7     Document Type: Article

References (32)

1. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, Global cancer statistics. 2002. CA Cancer J. Clin. 55, 74-108 (2005)
2. J. Xhu, Z. Chen, V. Lallemand-Breitenbach, H. de The, How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer 2, 705-713 (2002)
3. Z.Y. Wang, Z. Chen, Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111, 2505-2515 (2008)
4. X.W. Zhang, X.J. Yan, Z.R. Zhou, F.F. Yang, Z.Y. Wu, H.B. Sun, W.X. Liang, A.X. Song, V. Lallemand-Breitenbach, M. Jeanne, Q.Y. Zhang, H.Y. Yang, Q.H. Huang, G.B. Zhou, J.H. Tong, Y. Zhang, J.H. Wu, H.Y. Hu, H. de The, S.J. Chen, Z. Chen, Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328, 240-243 (2010)
5. V. Lallemand-Breitenbach, M. Jeanne, S. Benhenda, R. Nasr, M. Lei, L. Peres, J. Zhou, J. Zhu, B. Raught, H. de The, Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10, 547-555 (2008)
6. M.H. Tatham, M.C. Geoffroy, L. Shen, A. Plechanovova, N. Hattersley, E.G. Jaffray, J.J. Palvimo, R.T. Hay, RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10, 538-546 (2008)
7. D. Doucer, M.S. Tallman, Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol. 23, 2396-2410 (2005)
8. M.R. Litzow, S. Lee, J.M. Bennett, G.W. Dewald, R.E. Gallagher, V. Jain, E.M. Paietta, J. Racevskis, S.R. Rousey, J.J. Mazza, M.S. Tallman, A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica 91, 1105-1108 (2006)
9. J.H. Park, E.J. Kim, H.Y. Jang, H. Shim, K.K. Lee, H.J. Jo, H.J. Kim, S.H. Yang, E.T. Jeong, H.R. Kim, Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol. Rep. 20, 379-384 (2008)
10. X. Wang, G. Wang, D. Dong, S. Fu, B. Yang, Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide. Exp. Toxicol. Pathol. 60, 481-488 (2008)
11. B. Liu, S. Pan, X. Dong, H. Qiao, H. Jiang, G.W. Krissansen, X. Sun, Opposing effects of arsenic trioxide on hepatocellular carcinoma in mice. Cancer Sci. 97, 675-681 (2006)
12. S.Y. Woo, M.Y. Lee, Y.J. Jung, E.S. Yoo, J.Y. Seoh, H.Y. Shin, H.S. Ahn, K.H. Ryu, Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr. Hematol. Oncol. 23, 231-243 (2006)
13. P. Kumar, Q. Gao, Y. Ning, Z. Wang, P.H. Krebsbach, P.J. Polverini, Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Mol. Cancer Ther. 7, 2060-2069 (2008)
14. N. Zhang, Z.M. Wu, E. McGowan, J. Shi, Z.B. Hong, C.W. Ding, P. Xia, W. Di, Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 100, 2459-2464 (2009)
15. C. Nie, C. Tian, L. Zhao, P.X. Petit, M. Mehrpour, Q. Chen, Cysteine 62 of Bax is critical for its conformational activation and its proapoptotic activity in response to H2O2-induced apoptosis. J. Biol. Chem. 283, 15359-15369 (2008)
16. A. Ota, M. Yamamoto, T. Hori, S. Miyai, Y. Naishiro, H. Sohma, M. Maeda, Y. Kokai, Upregulation of plasma CCL8 in mouse model of graft-vs-host disease. Exp. Hematol. 37, 525-531 (2009)
17. T.C. Chou, P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22, 27-55 (1984)
18. T.C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006)
19. L. Zhang, K. Wang, F. Zhao, W. Hu, J. Chen, G.M. Lanza, B. Shen, B. Zhang, Near infrared imaging of EGFR of oral squamous cell carcinoma in mice administered arsenic trioxide. PLoS One 7, e46255 (2012)
20. C.W. Tsai, N.W. Chang, R.Y. Tsai, R.F. Wang, C.M. Hsu, S.S. Lin, C.N. Wu, S.S. Sun, M.H. Tsai, D.T. Bau, Synergistic cytotoxic effects of arsenic trioxide plus dithiothreitol on mice oral cancer cells. Anticancer Res. 30, 3655-3660 (2010)
21. Y. Jing, J. Dai, R.M. Chalmers-Redman, W.G. Tatton, S. Waxman, Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94, 2102-2111 (1999)
22. S.H. Kang, J.H. Song, H.K. Kang, S.J. Kim, H.W. Kang, Y.K. Lee, D.B. Park, Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells. Exp. Mol. Med. 35, 83-90 (2003)
23. M. Okamura, K. Hashimoto, J. Shimada, H. Sakagami, Apoptosis-inducing activity of cisplatin (CDDP) against human hepatoma and oral squamous cell carcinoma cell lines. Anticancer Res. 24, 655-661 (2004)
24. Y. Jing, J. Dai, R.M. Chalmers-Redman, W.G. Tatton, S. Waxman, Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94, 2102-2111 (1999)
25. E. Brown, C.G. Yedjou, P.B. Tchounwou, Cytotoxicity and oxidative stress in human liver carcinoma cells exposed to arsenic trioxide (HepG(2)). Met. Ions Biol. Med. 10, 583-587 (2008)
26. S. Urba, G. Wolf, A. Eisbruch, F. Worden, J. Lee, C. Bradford, T. Teknos, D. Chepeha, M. Prince, N. Hogikyan, J. Taylor, Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J. Clin. Oncol. 24, 593-598 (2006)
27. C. Andreadis, K. Vahtsevanos, T. Sidiras, I. Thomaidis, K. Antoniadis, D. Mouratidou, 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol. 39, 380-385 (2003)
28. E. Fox, B.I. Razzouk, B.C. Widemann, S. Xiao, M. O'Brien, W. Goodspeed, G.H. Reaman, S.M. Blaney, A.J. Murgo, F.M. Balis, P.C. Adamson, Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood 111, 566-573 (2008)
29. U. Kotowski, G. Heiduschka, M. Brunner, B.M. Erovic, H. Martinek, D. Thurnher, Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines. Oncol. Lett. 3, 1326-1330 (2012)
30. K.Y. Kim, H.J. Cho, S.N. Yu, S.H. Kim, H.S. Yu, Y.M. Park, N. Mirkheshti, S.Y. Kim, C.S. Song, B. Chatterjee, S.C. Ahn, Interplay of reactive oxygen species, intracellular Ca(2+) surge and loss of mitochondrial homeostasis in the apoptotic ablation of prostate cancer cells by deoxypodophyllotoxin. J. Cell. Biochem. 114, 1124-1134 (2013)
31. B.D. Bowling, N. Doudican, P. Manga, S.J. Orlow, Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism. Cancer Chemother. Pharmacol. 63, 37-43 (2008)
32. I. Jutooru, G. Chadalapaka, S. Sreevalsan, P. Lei, R. Barhoumi, R. Burghardt, S. Safe, Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp. Cell Res. 316, 2174-2188 (2010) Technology